Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Cash (2022 - 2025)

Historic Change in Cash for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$11.8 million.

  • Corvus Pharmaceuticals' Change in Cash fell 1636.65% to -$11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year increase of 8824.64%. This contributed to the annual value of -$3.9 million for FY2024, which is 61985.16% down from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Change in Cash of -$11.8 million as of Q3 2025, which was down 1636.65% from $9.7 million recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Change in Cash ranged from a high of $12.4 million in Q3 2023 and a low of -$32.0 million during Q1 2022
  • For the 4-year period, Corvus Pharmaceuticals' Change in Cash averaged around -$4.0 million, with its median value being -$3.7 million (2025).
  • Data for Corvus Pharmaceuticals' Change in Cash shows a peak YoY increase of 46999.0% (in 2024) and a maximum YoY decrease of 18163.41% (in 2024) over the last 5 years.
  • Over the past 4 years, Corvus Pharmaceuticals' Change in Cash (Quarter) stood at -$11.4 million in 2022, then skyrocketed by 34.51% to -$7.5 million in 2023, then skyrocketed by 154.24% to $4.1 million in 2024, then tumbled by 391.23% to -$11.8 million in 2025.
  • Its Change in Cash was -$11.8 million in Q3 2025, compared to $9.7 million in Q2 2025 and -$3.7 million in Q1 2025.